Diversity of myocardial involvement in systemic sclerosis: An 8-year study of 95 Japanese patients

I. Murata, K. Takenaka, S. Shinohara, T. Suzuki, T. Sasaki, K. Yamamoto

Research output: Contribution to journalArticle

Abstract

Background: Myocardial fibrosis has been reported to be an important complication of systemic sclerosis (SSc). Left ventricular (LV) hypertrophy has also been reported, but its significance is unclear. Correlations between cardiac complications and clinical or serologic subsets of SSc have not been previously evaluated by long-term observational studies. Methods: We correlated the findings of echocardiography, electrocardiography, and autopsy with clinical and serologic features in 95 patients with SSc who were monitored for up to 8 years. Results: Septal thickness determined by echocardiography was significantly greater in patients with anti-nuclear ribonucleoprotein (nRNP) antibodies than in patients with anti-Sc170 or anticentromere antibodies. Fractional shortening was reduced in patients with diffuse cutaneous involvement or anti-Sc170 antibodies. Ten patients had car pulmonale, which was confirmed by echocardiography. Four of them had diffuse cutaneous involvement and advanced pulmonary fibrosis, whereas four had anti- nRNP antibodies and mild or no fibrosis. Septal hypertrophy was detected in 12 patients, 10 of whom had limited cutaneous involvement and six had anti- nRNP antibodies. Diffuse or regional LV wall hypokinesia was seen in seven patients, of whom six had anti-Scl70 antibodies and five had diffuse cutaneous involvement. Six patients with car pulmonale, five with abnormal LV wall motion, and three with septal hypertrophy died during the follow-up period. Autopsy revealed LV hypertrophy in three with septal hypertrophy, disarray and irregular hypertrophy of myocytes in one of them, and extensive myocardial fibrosis in one with diffuse LV wall hypokinesia. Conclusions: Septal hypertrophy and car pulmonale caused by pulmonary vasculopathy were associated with limited cutaneous involvement or anti-nRNP antibodies, whereas abnormal LV wall motion and car pulmonale caused by advanced pulmonary fibrosis were mostly seen in patients with diffuse cutaneous involvement or anti-Sc170 antibodies.

Original languageEnglish (US)
Pages (from-to)960-969
Number of pages10
JournalAmerican Heart Journal
Volume135
Issue number6 I
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Systemic Scleroderma
Ribonucleoproteins
Hypertrophy
Skin
Anti-Idiotypic Antibodies
Echocardiography
Hypokinesia
Fibrosis
Antibodies
Pulmonary Fibrosis
Left Ventricular Hypertrophy
Autopsy
Muscle Cells
Observational Studies
Electrocardiography
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Diversity of myocardial involvement in systemic sclerosis : An 8-year study of 95 Japanese patients. / Murata, I.; Takenaka, K.; Shinohara, S.; Suzuki, T.; Sasaki, T.; Yamamoto, K.

In: American Heart Journal, Vol. 135, No. 6 I, 01.01.1998, p. 960-969.

Research output: Contribution to journalArticle

Murata, I. ; Takenaka, K. ; Shinohara, S. ; Suzuki, T. ; Sasaki, T. ; Yamamoto, K. / Diversity of myocardial involvement in systemic sclerosis : An 8-year study of 95 Japanese patients. In: American Heart Journal. 1998 ; Vol. 135, No. 6 I. pp. 960-969.
@article{94f9ff9f2e244f17892d44944d8b81d4,
title = "Diversity of myocardial involvement in systemic sclerosis: An 8-year study of 95 Japanese patients",
abstract = "Background: Myocardial fibrosis has been reported to be an important complication of systemic sclerosis (SSc). Left ventricular (LV) hypertrophy has also been reported, but its significance is unclear. Correlations between cardiac complications and clinical or serologic subsets of SSc have not been previously evaluated by long-term observational studies. Methods: We correlated the findings of echocardiography, electrocardiography, and autopsy with clinical and serologic features in 95 patients with SSc who were monitored for up to 8 years. Results: Septal thickness determined by echocardiography was significantly greater in patients with anti-nuclear ribonucleoprotein (nRNP) antibodies than in patients with anti-Sc170 or anticentromere antibodies. Fractional shortening was reduced in patients with diffuse cutaneous involvement or anti-Sc170 antibodies. Ten patients had car pulmonale, which was confirmed by echocardiography. Four of them had diffuse cutaneous involvement and advanced pulmonary fibrosis, whereas four had anti- nRNP antibodies and mild or no fibrosis. Septal hypertrophy was detected in 12 patients, 10 of whom had limited cutaneous involvement and six had anti- nRNP antibodies. Diffuse or regional LV wall hypokinesia was seen in seven patients, of whom six had anti-Scl70 antibodies and five had diffuse cutaneous involvement. Six patients with car pulmonale, five with abnormal LV wall motion, and three with septal hypertrophy died during the follow-up period. Autopsy revealed LV hypertrophy in three with septal hypertrophy, disarray and irregular hypertrophy of myocytes in one of them, and extensive myocardial fibrosis in one with diffuse LV wall hypokinesia. Conclusions: Septal hypertrophy and car pulmonale caused by pulmonary vasculopathy were associated with limited cutaneous involvement or anti-nRNP antibodies, whereas abnormal LV wall motion and car pulmonale caused by advanced pulmonary fibrosis were mostly seen in patients with diffuse cutaneous involvement or anti-Sc170 antibodies.",
author = "I. Murata and K. Takenaka and S. Shinohara and T. Suzuki and T. Sasaki and K. Yamamoto",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(98)70060-2",
language = "English (US)",
volume = "135",
pages = "960--969",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6 I",

}

TY - JOUR

T1 - Diversity of myocardial involvement in systemic sclerosis

T2 - An 8-year study of 95 Japanese patients

AU - Murata, I.

AU - Takenaka, K.

AU - Shinohara, S.

AU - Suzuki, T.

AU - Sasaki, T.

AU - Yamamoto, K.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Background: Myocardial fibrosis has been reported to be an important complication of systemic sclerosis (SSc). Left ventricular (LV) hypertrophy has also been reported, but its significance is unclear. Correlations between cardiac complications and clinical or serologic subsets of SSc have not been previously evaluated by long-term observational studies. Methods: We correlated the findings of echocardiography, electrocardiography, and autopsy with clinical and serologic features in 95 patients with SSc who were monitored for up to 8 years. Results: Septal thickness determined by echocardiography was significantly greater in patients with anti-nuclear ribonucleoprotein (nRNP) antibodies than in patients with anti-Sc170 or anticentromere antibodies. Fractional shortening was reduced in patients with diffuse cutaneous involvement or anti-Sc170 antibodies. Ten patients had car pulmonale, which was confirmed by echocardiography. Four of them had diffuse cutaneous involvement and advanced pulmonary fibrosis, whereas four had anti- nRNP antibodies and mild or no fibrosis. Septal hypertrophy was detected in 12 patients, 10 of whom had limited cutaneous involvement and six had anti- nRNP antibodies. Diffuse or regional LV wall hypokinesia was seen in seven patients, of whom six had anti-Scl70 antibodies and five had diffuse cutaneous involvement. Six patients with car pulmonale, five with abnormal LV wall motion, and three with septal hypertrophy died during the follow-up period. Autopsy revealed LV hypertrophy in three with septal hypertrophy, disarray and irregular hypertrophy of myocytes in one of them, and extensive myocardial fibrosis in one with diffuse LV wall hypokinesia. Conclusions: Septal hypertrophy and car pulmonale caused by pulmonary vasculopathy were associated with limited cutaneous involvement or anti-nRNP antibodies, whereas abnormal LV wall motion and car pulmonale caused by advanced pulmonary fibrosis were mostly seen in patients with diffuse cutaneous involvement or anti-Sc170 antibodies.

AB - Background: Myocardial fibrosis has been reported to be an important complication of systemic sclerosis (SSc). Left ventricular (LV) hypertrophy has also been reported, but its significance is unclear. Correlations between cardiac complications and clinical or serologic subsets of SSc have not been previously evaluated by long-term observational studies. Methods: We correlated the findings of echocardiography, electrocardiography, and autopsy with clinical and serologic features in 95 patients with SSc who were monitored for up to 8 years. Results: Septal thickness determined by echocardiography was significantly greater in patients with anti-nuclear ribonucleoprotein (nRNP) antibodies than in patients with anti-Sc170 or anticentromere antibodies. Fractional shortening was reduced in patients with diffuse cutaneous involvement or anti-Sc170 antibodies. Ten patients had car pulmonale, which was confirmed by echocardiography. Four of them had diffuse cutaneous involvement and advanced pulmonary fibrosis, whereas four had anti- nRNP antibodies and mild or no fibrosis. Septal hypertrophy was detected in 12 patients, 10 of whom had limited cutaneous involvement and six had anti- nRNP antibodies. Diffuse or regional LV wall hypokinesia was seen in seven patients, of whom six had anti-Scl70 antibodies and five had diffuse cutaneous involvement. Six patients with car pulmonale, five with abnormal LV wall motion, and three with septal hypertrophy died during the follow-up period. Autopsy revealed LV hypertrophy in three with septal hypertrophy, disarray and irregular hypertrophy of myocytes in one of them, and extensive myocardial fibrosis in one with diffuse LV wall hypokinesia. Conclusions: Septal hypertrophy and car pulmonale caused by pulmonary vasculopathy were associated with limited cutaneous involvement or anti-nRNP antibodies, whereas abnormal LV wall motion and car pulmonale caused by advanced pulmonary fibrosis were mostly seen in patients with diffuse cutaneous involvement or anti-Sc170 antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0031820565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031820565&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(98)70060-2

DO - 10.1016/S0002-8703(98)70060-2

M3 - Article

C2 - 9630099

AN - SCOPUS:0031820565

VL - 135

SP - 960

EP - 969

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6 I

ER -